Benzinga · Oct 27, 2026
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $10 price target.
HU
NASDAQ · HURA
TuHURA Biosciences, Inc.
Healthcare · Biotechnology
$1.93
Down-$0.13 (-6.31%)
Updated Nov 2, 2026, 12:05 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 52.85M
- P/E ratio
- -0.79
- Dividend yield
- 0.00%
- 52-week range
- $0.41 – $3.43
- Volume
- 524.07K
- Avg. volume
- 236.59K
Price performance · HURA
HURA price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
HURA closed at $1.93 after 20 trading sessions, up 3.21% for the selected period.
- Last close
- $1.93
- Period change
- +3.21%
- Period low
- $1.76
- Period high
- $2.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $2.05 | $2.05 | $1.85 | $1.93 | 524.07K |
| Oct 29, 2026 | $2.01 | $2.08 | $1.98 | $2.06 | 298.08K |
| Oct 28, 2026 | $2.075 | $2.12 | $1.93 | $1.99 | 569.4K |
| Oct 27, 2026 | $2.05 | $2.12 | $1.99 | $2.11 | 401.22K |
| Oct 26, 2026 | $2.205 | $2.23 | $1.9301 | $2.04 | 636.51K |
| Oct 23, 2026 | $2.07 | $2.185 | $2.05 | $2.18 | 1.01M |
| Oct 22, 2026 | $2.20 | $2.20 | $1.96 | $2.01 | 609.26K |
| Oct 21, 2026 | $1.74 | $2.1099 | $1.71 | $2.085 | 1.08M |
| Oct 20, 2026 | $1.77 | $1.81 | $1.75 | $1.76 | 39.15K |
| Oct 19, 2026 | $1.75 | $1.96 | $1.74 | $1.78 | 173.44K |
| Oct 16, 2026 | $1.81 | $1.85 | $1.76 | $1.76 | 86.04K |
| Oct 15, 2026 | $1.74 | $1.84 | $1.74 | $1.83 | 86.69K |
| Oct 14, 2026 | $1.78 | $1.78 | $1.7107 | $1.76 | 144.98K |
| Oct 13, 2026 | $1.91 | $1.91 | $1.80 | $1.81 | 354.66K |
| Oct 12, 2026 | $1.97 | $1.99 | $1.89 | $1.90 | 170.6K |
| Oct 9, 2026 | $1.95 | $1.99 | $1.95 | $1.96 | 148.97K |
| Oct 8, 2026 | $1.95 | $1.97 | $1.89 | $1.93 | 316.37K |
| Oct 7, 2026 | $1.91 | $2.00 | $1.871 | $1.98 | 140.45K |
| Oct 6, 2026 | $1.90 | $1.98 | $1.87 | $1.95 | 181.7K |
| Oct 5, 2026 | $1.94 | $1.94 | $1.85 | $1.87 | 335.53K |
Latest HURA news
The latest Smart Investors Daily articles mentioning HURA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HURA research
Overview
Company profile and research snapshot.
Company profile
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 18, 2026 | Citizens | Market Outperform | — |
| Apr 27, 2026 | Citizens | Market Outperform | — |
| Feb 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 26, 2026
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
TuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the first three evaluable patients treated in the frontline setting. Speaking duri
Yahoo · Oct 26, 2026
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda® in first-line treatment of metastatic Merkel Cell Carcinoma (MCC). Results showed that each patient achieved a major objective anti-tumor response, with all three responses meeting the cr
Benzinga · Oct 26, 2026
TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda
Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Company to host a webcast today, October 26, 2026, at 8:30 am ETTAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
